长春瑞滨联合顺铂与紫杉醇联合顺铂方案治疗晚期非小细胞肺癌的疗效比较

目的：比较NP和TP方案治疗晚期非小细胞肺癌的疗效和毒副反应。方法：61例经病理或细胞学证实的晚期非小细胞肺癌患者随机分为两组，NP组30例，TP组31例。NP组：NVB25mg／m^2，静注，第1、8天；PDD20mg／m^2，静脉滴注，第1—5天。IP组：PTX135mg／m^2，静脉滴注，第1天，持续3—4小时；PDD20mg／m^2，第2—6天。2—3周为一周期。结果：NP组30例，总有效率40．0％，1年生存率为36．7％，中位生存期10．7个月；TP组31例，总有效率45．2％，1年生存率41．9％，中位生存期10．2个月。两组间总有效率、1年生存率比较差异均无显著性（P〉0．05）。骨髓抑制为主要的剂量限制性毒性，NP组较TP组稍重，白细胞减少发生率分别为86．7％和67．7％。NP组静脉炎和胃道肠反应较TP组重，而TP组脱发和周围神经毒性／疼痛较NP组重。结论：NP方案和TP方案治疗晚期非小细胞肺癌疗效肯定，毒性反应可以耐受。两方案疗效差异无显著性。

Vinorelbine plus cisplatin vs Paclitaxel plus cisplatin in treatment of patients with advanced non - small - cell lung cancer

Objective:To compare the efficacy and toxicity of vinorelbine plus cisplatin(NP)and paclitaxel plus cisplatin(TP)combinations in the treatment of advanced non-small-cell lung cancer(NSCLC).Methods:61patients with advanced NSCLC were randomized to receive vinorelbine 25mg/m~2 on the 1stand 8th day by infusion and cisplatin 20mg/m~2 from the 1st to the 5th day(group NP,30 patients),or paclitaxel 135mg/m~2 on the 1st day by infusion and cisplatin 20mg/m~2 for 3~4 hours from the 2nd to 6th day(group TP,31 patients).Both regimens were repeated every 3 weeks.Results:Objective response rate of 40.0% was observed in NP group versus 45.2% in TP group(P>0.05).The 1-year survival rate was 36.7% in NP group and 41.9% in TP group(P>0.05).The median survival duration was 10.7 months in NP group and 10.2 months in TP group.Myelosuppression was major dose-limiting toxicity.The incidence of neutropenia were 86.7% in NP group,and 67.7% in TP group.Phlebitis and nausea/vomiting were more severe in NP groug.By contrast,alopecia and peripheral neutrotoxicity/myalgia were more frequent in TP roup.Conclusion:The NP combination is as equally active and well tolerated as the TP combination in patients with advanced non-small-cell lung cancer.